{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T08:04:44Z","timestamp":1784016284265,"version":"3.55.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jamda.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Medical Directors Association"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jamda.2025.106036","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T04:30:17Z","timestamp":1767673817000},"page":"106036","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Prescription Patterns and Associated Factors of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors Use Among Patients Worldwide: A Systematic Review and Meta-Analysis of Real-World Studies"],"prefix":"10.1016","volume":"27","author":[{"given":"Man","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanzhi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jamda.2025.106036_bib1","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2991\/jegh.k.191028.001","article-title":"Epidemiology of type 2 diabetes - global burden of disease and forecasted trends","volume":"10","author":"Khan","year":"2020","journal-title":"J Epidemiol Glob Health"},{"key":"10.1016\/j.jamda.2025.106036_bib2","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/eurjpc\/zwab034","article-title":"Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin","volume":"29","author":"Fontes-Carvalho","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jamda.2025.106036_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000520909","article-title":"Heart failure in patients with diabetes and chronic kidney disease: challenges and opportunities","volume":"12","author":"Vijay","year":"2022","journal-title":"Cardiorenal Med"},{"key":"10.1016\/j.jamda.2025.106036_bib4","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.2337\/dc22-0614","article-title":"Prescription patterns of cardiovascular- and kidney-protective therapies among patients with type 2 diabetes and chronic kidney disease","volume":"45","author":"Lamprea-Montealegre","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jamda.2025.106036_bib5","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1016\/j.jacc.2020.02.056","article-title":"Diabetic agents, from metformin to SGLT2 inhibitors and GLP1 receptor agonists: JACC focus seminar","volume":"75","author":"Wilcox","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jamda.2025.106036_bib6","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1186\/s12933-023-02023-y","article-title":"Sodium-glucose cotransporter-2 inhibition for heart failure with preserved ejection fraction and chronic kidney disease with or without type 2 diabetes mellitus: a narrative review","volume":"22","author":"Mentz","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.jamda.2025.106036_bib7","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jamda.2025.106036_bib8","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 inhibitors with cardiovascular and kidney outcomes in patients with type 2 diabetes: a meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jamda.2025.106036_bib9","first-page":"315","article-title":"Guideline for the prevention and treatment of type 2 diabetes mellitus in China (2020 edition)","volume":"13","year":"2021","journal-title":"Chin J Diabetes Mellitus"},{"key":"10.1016\/j.jamda.2025.106036_bib10","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.06.019","article-title":"KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease","volume":"98","year":"2020","journal-title":"Kidney Int"},{"key":"10.1016\/j.jamda.2025.106036_bib11","doi-asserted-by":"crossref","first-page":"S203","DOI":"10.2337\/dc20-S016","article-title":"16. Diabetes advocacy: standards of medical care in diabetes\u20142019","volume":"43","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jamda.2025.106036_bib12","author":"Herrington"},{"key":"10.1016\/j.jamda.2025.106036_bib13","doi-asserted-by":"crossref","first-page":"701","DOI":"10.4093\/dmj.2022.0002","article-title":"Real-world prescription patterns and barriers related to the use of sodium-glucose cotransporter 2 inhibitors among korean patients with type 2 diabetes mellitus and cardiovascular disease","volume":"46","author":"Baek","year":"2022","journal-title":"Diabetes Metab J"},{"key":"10.1016\/j.jamda.2025.106036_bib14","doi-asserted-by":"crossref","first-page":"5969","DOI":"10.1038\/s41598-023-33211-1","article-title":"Integrated analysis for treatment scheme of sodium-glucose cotransporter 2 inhibitors in patients with diabetic kidney disease: a real-world study","volume":"13","author":"Fang","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.jamda.2025.106036_bib15","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.jacc.2024.05.057","article-title":"Prescription patterns for sodium-glucose cotransporter 2 inhibitors in U.S. health systems","volume":"84","author":"Shin","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jamda.2025.106036_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102426","article-title":"Implementation of chronic kidney disease guidelines for sodium-glucose co-transporter-2 inhibitor use in primary care in the UK: a cross-sectional study","volume":"68","author":"Forbes","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jamda.2025.106036_bib17","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jamda.2025.106036_bib18","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/XEB.0000000000000054","article-title":"Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data","volume":"13","author":"Munn","year":"2015","journal-title":"Int J Evid Based Healthc"},{"key":"10.1016\/j.jamda.2025.106036_bib19","author":"Wells"},{"key":"10.1016\/j.jamda.2025.106036_bib20","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/bjsports-2017-098890","article-title":"Risk factors for patellofemoral pain: a systematic review and meta-analysis","volume":"53","author":"Neal","year":"2019","journal-title":"Br J Sports Med"},{"key":"10.1016\/j.jamda.2025.106036_bib21","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.jamda.2025.106036_bib22","series-title":"Cochrane Handbook for Systematic Reviews of Interventions version 6.5","author":"Higgins","year":"2024"},{"key":"10.1016\/j.jamda.2025.106036_bib23","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.jamda.2025.106036_bib24","first-page":"390","article-title":"Incidence and prevalence of falls in adults with intellectual disability living in the community: a systematic review","volume":"17","author":"Ho","year":"2019","journal-title":"Database Syst Rev Implement Rep"},{"key":"10.1016\/j.jamda.2025.106036_bib25","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jamda.2025.106036_bib26","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1056\/NEJMoa2206286","article-title":"Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction","volume":"387","author":"Solomon","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jamda.2025.106036_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF diabetes atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.jamda.2025.106036_bib28","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1016\/S0140-6736(06)69703-1","article-title":"Epidemic obesity and type 2 diabetes in Asia","volume":"368","author":"Yoon","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.jamda.2025.106036_bib29","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.6139","article-title":"Association of race\/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US","volume":"4","author":"Eberly","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jamda.2025.106036_bib30","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1038\/s41598-017-02733-w","article-title":"Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"7","author":"Liu","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.jamda.2025.106036_bib31","doi-asserted-by":"crossref","first-page":"2963","DOI":"10.1111\/dom.15193","article-title":"Safety of sodium-glucose cotransporter 2 inhibitors in elderly patients with type 2 diabetes: a meta-analysis of randomized controlled trials","volume":"25","author":"Rigato","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jamda.2025.106036_bib32","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1001\/jama.2024.27402","article-title":"Age and sex differences in efficacy of treatments for type 2 diabetes: a network meta-analysis","volume":"333","author":"Hanlon","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.jamda.2025.106036_bib33","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s11892-024-01537-3","article-title":"Diabetes, SGLT-2 inhibitors, and urinary tract infection: a review","volume":"24","author":"Pishdad","year":"2024","journal-title":"Curr Diab Rep"},{"key":"10.1016\/j.jamda.2025.106036_bib34","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1002\/phar.2458","article-title":"Characterization of risk factors for genitourinary infections with sodium-glucose cotransporter-2 inhibitors","volume":"40","author":"Benjamin","year":"2020","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.jamda.2025.106036_bib35","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/dom.13876","article-title":"Effects of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes in women versus men","volume":"22","author":"R\u00e5dholm","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jamda.2025.106036_bib36","article-title":"Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes","volume":"34","author":"Rodriguez","year":"2024","journal-title":"Lancet Reg Health Am"},{"key":"10.1016\/j.jamda.2025.106036_bib37","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1681\/ASN.0000000000000466","article-title":"Sodium-clucose cotransporter 2 inhibitors in older patients with CKD","volume":"35","author":"Bakker","year":"2024","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jamda.2025.106036_bib38","article-title":"Effects of sodium-glucose cotransporter 2 inhibitors on body weight, BMI, and body composition in adults with type 2 diabetes mellitus: a systematic review","volume":"16","author":"Naeem","year":"2024","journal-title":"Cureus"},{"key":"10.1016\/j.jamda.2025.106036_bib39","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2217\/cer-2019-0002","article-title":"Treatment patterns, glycemic control and bodyweight with canagliflozin 300 mg versus GLP1RAs in type II diabetes patients","volume":"8","author":"Coleman","year":"2019","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.jamda.2025.106036_bib40","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1097\/XCE.0000000000000195","article-title":"Relative frequency of cardiology vs. endocrinology visits by type 2 diabetes patients with cardiovascular disease in the USA: implications for implementing evidence-based use of glucose-lowering medications","volume":"9","author":"Gunawan","year":"2020","journal-title":"Cardiovasc Endocrinol Metab"},{"key":"10.1016\/j.jamda.2025.106036_bib41","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.2215\/CJN.08900722","article-title":"Estimated lifetime benefit of combined RAAS and SGLT2 inhibitor therapy in patients with albuminuric CKD without diabetes","volume":"17","author":"Vart","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.jamda.2025.106036_bib42","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1161\/CIRCULATIONAHA.123.067584","article-title":"Estimated lifetime cardiovascular, kidney, and mortality benefits of combination treatment with SGLT2 inhibitors, GLP-1 receptor agonists, and nonsteroidal MRA compared with conventional care in patients with type 2 diabetes and albuminuria","volume":"149","author":"Neuen","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jamda.2025.106036_bib43","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/fcp.12792","article-title":"Increased risk of urinary tract infection and pyelonephritis under concomitant use of sodium-dependent glucose cotransporter 2 inhibitors with antidiabetic, antidyslipidemic, and antihypertensive drugs: an observational study","volume":"36","author":"Tada","year":"2022","journal-title":"Fundam Clin Pharmacol"}],"container-title":["Journal of the American Medical Directors Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525861025005535?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525861025005535?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T07:24:21Z","timestamp":1784013861000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525861025005535"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":43,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S1525861025005535"],"URL":"https:\/\/doi.org\/10.1016\/j.jamda.2025.106036","relation":{},"ISSN":["1525-8610"],"issn-type":[{"value":"1525-8610","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prescription Patterns and Associated Factors of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors Use Among Patients Worldwide: A Systematic Review and Meta-Analysis of Real-World Studies","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Medical Directors Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jamda.2025.106036","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Post-Acute and Long-Term Care Medical Association.","name":"copyright","label":"Copyright"}],"article-number":"106036"}}